HRTX
Income statement / Annual
Last year (2023), Heron Therapeutics, Inc.'s total revenue was $127.04 M,
an increase of 17.99% from the previous year.
In 2023, Heron Therapeutics, Inc.'s net income was -$110.56 M.
See Heron Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$127.04 M
|
$107.67 M
|
$86.35 M
|
$88.64 M
|
$145.97 M
|
$77.47 M
|
$30.77 M
|
$1.28 M
|
$0.00
|
$0.00
|
| Cost of Revenue |
$65.11 M |
$54.87 M |
$46.02 M |
$36.19 M |
$61.62 M |
$27.51 M |
$4.59 M |
$35,000.00 |
$734,000.00 |
$54.83 M |
| Gross Profit |
$61.94 M |
$52.80 M |
$40.33 M |
$52.45 M |
$84.35 M |
$49.96 M |
$26.18 M |
$1.24 M |
-$734,000.00 |
-$54.83 M |
| Gross Profit Ratio |
0.49 |
0.49 |
0.47 |
0.59 |
0.58 |
0.64 |
0.85 |
0.97 |
0 |
0 |
| Research and Development
Expenses |
$55.90 M
|
$107.51 M
|
$130.82 M
|
$174.53 M
|
$167.38 M
|
$140.03 M
|
$138.58 M
|
$103.13 M
|
$61.18 M
|
$54.83 M
|
| General & Administrative
Expenses |
$49.01 M
|
$37.44 M
|
$40.15 M
|
$42.23 M
|
$37.90 M
|
$29.26 M
|
$25.55 M
|
$21.37 M
|
$35.74 M
|
$19.73 M
|
| Selling & Marketing
Expenses |
$67.64 M
|
$82.51 M
|
$87.18 M
|
$63.85 M
|
$89.76 M
|
$64.60 M
|
$56.60 M
|
$47.67 M
|
$17.35 M
|
$8.71 M
|
| Selling, General &
Administrative Expenses |
$116.66 M
|
$119.95 M
|
$127.33 M
|
$106.08 M
|
$127.66 M
|
$93.87 M
|
$82.16 M
|
$69.03 M
|
$35.74 M
|
$19.73 M
|
| Other Expenses |
$0.00 |
-$7.37 M |
-$2.86 M |
$885,000.00 |
$5.95 M |
$5.10 M |
-$38,000.00 |
-$2.23 M |
-$666,000.00 |
-$1.81 M |
| Operating Expenses |
$172.55 M |
$227.46 M |
$258.15 M |
$280.61 M |
$295.04 M |
$233.90 M |
$220.74 M |
$172.16 M |
$96.93 M |
$74.56 M |
| Cost And Expenses |
$237.66 M |
$282.33 M |
$304.17 M |
$316.80 M |
$356.66 M |
$261.41 M |
$225.33 M |
$172.19 M |
$96.93 M |
$74.56 M |
| Interest Income |
$3.36 M |
$1.64 M |
$433,000.00 |
$3.63 M |
$7.26 M |
$5.97 M |
$1.05 M |
$445,000.00 |
$0.00 |
$0.00 |
| Interest Expense |
$3.87 M |
$2.47 M |
$2.41 M |
$1.90 M |
$1.47 M |
$2.67 M |
$3.94 M |
$2.66 M |
$958,000.00 |
$887,000.00 |
| Depreciation &
Amortization |
$2.90 M
|
$2.89 M
|
$3.02 M
|
$2.85 M
|
$2.04 M
|
$1.51 M
|
$1.53 M
|
$1.10 M
|
$734,000.00
|
$578,000.00
|
| EBITDA |
-$103.79 M
|
-$176.66 M
|
-$215.25 M
|
-$222.53 M
|
-$201.23 M
|
-$174.66 M
|
-$192.02 M
|
-$169.38 M
|
-$96.19 M
|
-$73.98 M
|
| EBITDA Ratio |
-0.82 |
-1.62 |
-2.52 |
-2.57 |
-1.43 |
-2.37 |
-6.24 |
-133.63 |
0 |
0 |
| Operating Income Ratio
|
-0.87
|
-1.62
|
-2.52
|
-2.57
|
-1.44
|
-2.37
|
-6.32
|
-133.63
|
0
|
0
|
| Total Other
Income/Expenses Net |
$56,000.00
|
-$7.37 M
|
-$2.86 M
|
$885,000.00
|
$5.95 M
|
$5.10 M
|
-$2.93 M
|
-$2.23 M
|
-$666,000.00
|
-$1.81 M
|
| Income Before Tax |
-$110.56 M |
-$182.02 M |
-$220.68 M |
-$227.28 M |
-$204.75 M |
-$178.84 M |
-$197.48 M |
-$173.14 M |
-$97.59 M |
-$76.37 M |
| Income Before Tax Ratio
|
-0.87
|
-1.69
|
-2.56
|
-2.56
|
-1.4
|
-2.31
|
-6.42
|
-135.37
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$47.51 M |
-$3.02 M |
-$2.85 M |
$1.87 M |
$7.77 M |
$3.90 M |
-$1.10 M |
-$734,000.00 |
-$578,000.00 |
| Net Income |
-$110.56 M |
-$134.52 M |
-$217.66 M |
-$224.43 M |
-$204.75 M |
-$178.84 M |
-$197.48 M |
-$173.14 M |
-$97.59 M |
-$76.37 M |
| Net Income Ratio |
-0.87 |
-1.25 |
-2.52 |
-2.53 |
-1.4 |
-2.31 |
-6.42 |
-135.37 |
0 |
0 |
| EPS |
-0.8 |
-1.24 |
-2.21 |
-2.47 |
-2.5 |
-2.44 |
-3.65 |
-4.57 |
-2.95 |
-2.87 |
| EPS Diluted |
-0.8 |
-1.24 |
-2.21 |
-2.47 |
-2.5 |
-2.44 |
-3.65 |
-4.57 |
-2.95 |
-2.87 |
| Weighted Average Shares
Out |
$138.14 M
|
$108.88 M
|
$98.47 M
|
$90.77 M
|
$81.78 M
|
$73.19 M
|
$54.04 M
|
$37.93 M
|
$33.08 M
|
$26.57 M
|
| Weighted Average Shares
Out Diluted |
$138.14 M
|
$108.88 M
|
$98.47 M
|
$90.77 M
|
$81.78 M
|
$73.19 M
|
$54.04 M
|
$37.93 M
|
$33.08 M
|
$26.57 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
